Schonfeld Strategic Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,800	Closed	-$59.6K	–	2166
2025 Q1	$59.6K	Buy	+10,800	New	+$66.7K	﹤0.01%	2063
2022 Q4	–	Sell	-23,415	Closed	-$1.22M	–	2689
2022 Q3	$1.22M	Buy	+23,415	New	+$1.37M	0.01%	1150
2022 Q1	–	Sell	-5,700	Closed	-$426K	–	2675
2021 Q4	$426K	Buy	+5,700	New	+$447K	﹤0.01%	1341
2020 Q2	–	Sell	-4,925	Closed	-$253K	–	1320
2020 Q1	$253K	Buy	+4,925	New	+$262K	0.02%	820
2017 Q4	–	Sell	-6,427	Closed	-$301K	–	765
2017 Q3	$301K	Buy	+6,427	New	+$258K	0.03%	450
2017 Q2	–	Sell	-9,336	Closed	-$288K	–	651
2017 Q1	$288K	Buy	+9,336	New	+$291K	0.03%	479
2016 Q4	–	Sell	-11,376	Closed	-$303K	–	573
2016 Q3	$303K	Sell	11,376 -3,639	-24%	-$84.5K	0.05%	315
2016 Q2	$331K	Buy	15,015 +2,907	+24%	+$76.1K	0.07%	296
2016 Q1	$356K	Buy	+12,108	New	+$337K	0.15%	188

Other funds holding ENTA

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schonfeld Strategic Advisors's ENTA Position: Q2 2025 in Review

Schonfeld Strategic Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q2 2025, closing a stake of 10,800 shares — an estimated $59.6K sold.

Schonfeld Strategic Advisors first reported a position in ENTA in Q1 2016 and held it in 9 quarters. The position peaked at $1.22M in Q3 2022. 107 funds tracked by Wall St. Rank hold ENTA as of Q2 2025.

Schonfeld Strategic Advisors reported no remaining Enanta Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Schonfeld Strategic Advisors sold 10,800 Enanta Pharmaceuticals shares in Q2 2025, an estimated $59.6K.
Schonfeld Strategic Advisors first reported a position in Enanta Pharmaceuticals in Q1 2016 and held it in 9 quarters.
Schonfeld Strategic Advisors's Enanta Pharmaceuticals position peaked at $1.22M in Q3 2022.
107 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.